Search
monoclonal antibody AMG 145
Indications:
- dyslipidemia, with increased LDL cholesterol
- may be used with statin
Mechanism of action:
- inhibits PCSK9
- decreases LDL cholesterol (50%)
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
PCSK9 inhibitor (ALN-PCS)
pharmaceutical monoclonal antibody
References
- Giugliano RP et al
Efficacy, safety, and tolerability of a monoclonal antibody
to proprotein convertase subtilisin/kexin type 9 in combination
with a statin in patients with hypercholesterolaemia
(LAPLACE-TIMI 57): a randomised, placebo-controlled,
dose-ranging, phase 2 study
The Lancet, Early Online Publication, 6 November 2012
PMID: 23141813
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61770-X/abstract
- Koren MJ et al
Efficacy, safety, and tolerability of a monoclonal antibody
to proprotein convertase subtilisin/kexin type 9 as monotherapy
in patients with hypercholesterolaemia (MENDEL): a randomised,
double-blind, placebo-controlled, phase 2 study
The Lancet, Early Online Publication, 6 November 2012
PMID: 23141812
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61771-1/abstract
- Tonkin AM and Watts GF
Into the future: diversifying lipid management
The Lancet, Early Online Publication, 6 November 2012
PMID: 23141810
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61888-1/fulltext
- Raal F et al
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a
Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9
Serine Protease in Patients With Heterozygous Familial
Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition
in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD)
Randomized Trial.
Circulation. 2012 Nov 5. [Epub ahead of print]
PMID: 23129602
- Sullivan D et al
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein
Cholesterol Levels in Statin-Intolerant Patients: The GAUSS
Randomized Trial.
JAMA. 2012 Nov 5:1-10
PMID: 23128163